We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

61 hedge funds and large institutions have $34.8M invested in Matinas BioPharma in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

0.02% less ownership

Funds ownership: 0.48% → 0.46% (-0.02%)

5% less capital invested

Capital invested by funds: $36.7M → $34.8M (-$1.91M)

6% less funds holding

Funds holding: 65 → 61 (-4)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
61
Holders Change
-4
Holders Change %
-6.15%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
13
Reduced
8
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
+$479K
2
SIG
Sargent Investment Group
Maryland
+$364K
3
Two Sigma Investments
Two Sigma Investments
New York
+$148K
4
WG
Winton Group
United Kingdom
+$109K
5
BCM
Bridgeway Capital Management
Texas
+$104K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$1.62M
2
Millennium Management
Millennium Management
New York
-$279K
3
Renaissance Technologies
Renaissance Technologies
New York
-$206K
4
Jane Street
Jane Street
New York
-$199K
5
Wells Fargo
Wells Fargo
California
-$153K
Name Holding Trade Value Shares
Change 		Change in
Stake
CDH
26
Charles D. Hyman
$61K – – –
Citadel Advisors
27
Citadel Advisors
Florida
$56K -$34.5K -868 -37%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$50K +$51.4K +1,293 New
MA
29
MONECO Advisors
Connecticut
$46K – – –
Stifel Financial
30
Stifel Financial
Missouri
$42K +$15.9K +400 +57%
JP Morgan Chase
31
JP Morgan Chase
New York
$35K – – –
Charles Schwab
32
Charles Schwab
California
$27K – – –
AWA
33
Arete Wealth Advisors
Illinois
$23K – – –
CWM
34
CCG Wealth Management
California
$23K – – –
IFG
35
Investors Financial Group
Minnesota
$23K +$15.9K +400 +200%
Morgan Stanley
36
Morgan Stanley
New York
$23K +$17.6K +443 +282%
Commonwealth Equity Services
37
Commonwealth Equity Services
Massachusetts
$20K – – –
DAS
38
Dynamic Advisor Solutions
Arizona
$16K – – –
Janney Montgomery Scott
39
Janney Montgomery Scott
Pennsylvania
$15K – – –
RC
40
RegentAtlantic Capital
New Jersey
$15K – – –
Osaic Holdings
41
Osaic Holdings
Arizona
$15K +$11.1K +280 +233%
NRS
42
Neville Rodie & Shaw
New York
$13K – – –
SBWIC
43
Schaper Benz & Wise Investment Counsel
Wisconsin
$11K – – –
FI
44
FormulaFolio Investments
Michigan
$10K +$9.94K +250 New
Barclays
45
Barclays
United Kingdom
$10K +$10K +252 New
EWM
46
Endurance Wealth Management
Rhode Island
$10K +$10.5K +265 New
BJL
47
Brighton Jones LLC
Washington
$8K -$63.6K -1,600 -89%
CFS
48
CRA Financial Services
New Jersey
$8K – – –
FAIM
49
Financial Advocates Investment Management
Washington
$8K – – –
FC
50
Fore Capital
New York
$8K – – –
1
2
3

MTNB Hedge Fund Activity: Q3 2020 in Review

61 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2020, worth a combined $34.8M — down 5.2% from $36.7M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of MTNB and 7 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 13 added.

The largest buyer was Two Sigma Advisers, adding an estimated $479K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.62M sold.

  • 61 institutional investors held Matinas BioPharma (MTNB) as of Q3 2020, down from 65 in Q2 2020.
  • Funds reported $34.8M of Matinas BioPharma stock for Q3 2020, down 5.2% quarter-over-quarter.
  • 7 funds opened new Matinas BioPharma positions in Q3 2020 and 11 closed out, a net change of -4 holders.
  • The largest Matinas BioPharma buyer in Q3 2020 was Two Sigma Advisers, an estimated $479K added.
  • The largest Matinas BioPharma seller in Q3 2020 was Baker Bros. Advisors, an estimated $1.62M sold.

Based on aggregated 13F filings for Q3 2020.